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The National Policy of Integrative and Complementary Practices (PNPIC) in the Brazilian Unified 
Health System (SUS), and The National Policy of Medicinal Plants and Herbal Medicines (PNPMF) 
were launched in 2006. Based on these, the Brazilian Health Surveillance Agency (ANVISA) re-edited 
rules related to herbal medicines such as the Guideline to herbal medicine registration (RDC 14/10), the 
Good Manufacture Practices Guideline (RDC 17/10) and the List of references to assess the safety and 
efficacy of herbal medicines (IN 05/10). The requisites to prove herbal medicine’s safety and efficacy 
were updated. Therefore, this review aims at presenting and commenting these new rules.
Uniterms: Herbal medicines / Regulation. Herbal medicines / Quality control. Medicines / Good 
Manufacture Practices. Pharmaceutical industry.
Em 2006, dois importantes documentos foram publicados no Brasil: a Política Nacional de Práticas 
Integrativas e Complementares (PNPIC) no Sistema Único de Saúde (SUS) e a Política Nacional de 
Plantas Medicinais e Fitoterápicos (PNPMF) à luz das quais a ANVISA avaliou as normas para o setor. 
Como produto dessa avaliação, foram republicadas as normas para registro de medicamentos fitoterápicos, 
por meio da Resolução de Diretoria Colegiada (RDC) 14/10, as Boas Práticas de Fabricação e Controle 
de medicamentos na indústria farmacêutica, RDC 17/10, e a lista de referências para comprovação 
da segurança e eficácia de medicamentos fitoterápicos, na forma da Instrução Normativa (IN) 05/10. 
Em relação às normas anteriormente vigentes, foram atualizados os requisitos para comprovação da 
segurança e eficácia destes medicamentos e sugeridas alternativas ao controle da qualidade de cada 
etapa de produção. Dessa forma, essa revisão tem por objetivo apresentar tais normas destacando suas 
características principais.
Unitermos: Medicamento fitoterápico / Regulamentação. Medicamento fitoterápico / Controle de 
qualidade. Medicamentos / Boas Práticas de Fabricação. Indústria farmacêutica.
INTRODUCTION
Within the context of the supply chain of medicinal 
plants and herbal medicines, the Brazilian health legis-
lation, which provides for herbal medicines registration, 
has recently been updated and published as RDC 14/10, 
in line with the scientific and technological developments 
enabling the expansion of the population’s access to these 
medicines (Brasil, 2010b).
Herbal Medicine is the technically prepared, indus-
trialized product derived from active raw plant material 
and it is supposed to feature reproducibility and constancy 
of quality. Notably, any product that includes natural or 
synthetic isolated active substances alone, or added to the 
plant derivative, cannot be classified as a herbal medicine 
(Brasil, 2010b).
Herbal medicines have always accounted for a sig-
nificant portion of the medicine market. The industry is 
worth $ 21.7 billion per year worldwide and in Brazil alone 
this market generates $ 160 million annually. This amount 
does not include the relatively broad popular market found 
mainly within the country. The attraction of this market is 
the pace of sales growth, over 15% annually, against 4% 
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obtained from the sale of synthetic drugs. Considering the 
whole production chain, herbal medicines generate about 
$ 1 billion annually (FEBRAFARMA, 2007). 
In recent decades, efforts in Brazil have been 
undertaken to stimulate studies of medicinal plants, to 
promote training of qualified personnel on research, and 
to introduce herbal alternatives into basic health care 
(Brasil, 2006b). However, only in 2006 did the Brazilian 
Government define policies, considered a milestone for 
the industry of medicinal plants and herbal medicines at 
the time, in the form of the PNPIC (Ministerial GM/MS 
971/06) and PNPMF (Decree 5,813/06). These policies 
contain among their guidelines, fostering of research on 
medicinal plants and development of herbal medicines of 
quality, safety and efficacy standards that must be made 
available to the population while prioritizing the protection 
of biodiversity and promoting greater access to safe and 
effective treatments (Brasil, 2006a,b). 
The Brazilian Health Surveillance System, coordi-
nated by ANVISA, is responsible for assessing the herbal 
medicine industry in Brazil, while State and Municipal 
assessments are performed by their respective local gover-
nments. Therefore, these two policies govern surveillance 
of marketing, dispensing, handling and distribution of raw 
materials of plant origin, as well as the registration and 
supervision of herbal medicine production (Brasil, 1999). 
Herbal medicine registration was historically con-
trolled by five specific regulatory rules in Brazil: Minis-
terial Directives 22 (30 October 1967) (Brasil, 1967), 06 
(31 January 1995) (Brasil, 1995), and RDCs 17 (April 23, 
2000) (Brasil, 2000), 48 (16 March 2004) (Brasil, 2004a) 
and 14 (01 April 2010) (Brasil, 2010b). 
The legislation taking effect is the newly published 
RDC 14/10 which differs from its predecessor mainly on 
the following items: alternative points for quality control 
of each pharmaceutical production step; registration per-
mit for medicines that contain herbal drugs as their active 
substance, as long as pre-clinical tests and clinical trials 
are provided to prove safety and efficacy for the particular 
pharmaceu tical form one wishes to register; requirement 
of aflatoxin evaluation test, in some cases as suggested by 
official monographs or the literature; inclusion of multi-
cellular fungi and algae registration whenever a specific 
regulation has not yet been published (Brasil, 2010b). 
It is estimated that there are 512 herbal medicines 
registered in ANVISA’s records derived from approxi-
mately 162 medicinal plant extracts and other derivatives 
(Carvalho et al., 2008a). Despite being a country that is 
home to 15-20% of the total number of species on the 
planet and having a long acceptance of use of medicinal 
plants among its population (Rodrigues, 2006), only 25% 
of the registered herbal medicines in Brazil come from 
existing medicinal species in South America (Carvalho 
et al., 2008b). Therefore, it is important that researchers 
look to health legislation and take a more focused ap-
proach on the productive sector in order to generate more 
information on the Brazilian plant species available, and 
to ensure more herbal medicines products are registered 
(Toledo et al., 2003).
HERBAL MEDICINE REGISTRATION IN BRAZIL
The registration of pharmaceuticals follows para-
meters so as to demonstrate the quality, effectiveness and 
safety of the product. The registration dossier consists of 
a documentary part, a technical report containing data on 
pro duction and quality control, and a safety and efficacy 
report. 
Herbal medicines can be registered only by phar-
maceutical industries previously authorized by ANVISA 
to manufacture these products. The company must also 
confirm that it is able to manufacture pharmaceuticals 
in accordance with the Good Manufacturing Practices 
and Con trol protocol (BPFC). In order to achieve this 
certification, the company must follow internationally 
standardized norms, internalized in Brazil by the newly 
published RDC 17/10 (Brasil, 2010a). For herbal medicine 
production, industries must prove they have employed a 
qualified pharmacist who will be the technically respon-
sibly officer for the product.
SAFETY AND EFFICACY INFORMATION 
Requirements for proof of safety and efficacy of 
herbal medicines have not essentially changed since RDC 
48/04 (Brasil, 2004a). Companies must submit one of the 
following alternatives: preclinical and clinical safety and 
efficacy trials must be carried out, as required to register 
any other medicine in Brazil; these tests may be exempted 
if the plant is included in the “list of simplified registration 
of herbal medicines” (Brasil, 2008b) or if there is sufficient 
data in the literature validating its safety and efficacy. This 
validation is a score that can be obtained from a list of 
standard technical-scientific literature and books, all com-
piled in IN 05/10 (Brasil, 2010c). The fourth alternative is 
attesting the traditional use of the product. 
IN 05/10 encompasses the “list of bibliographic refe-
rences for assessment of safety and efficacy of her bal me-
dicines” and presents 35 reference books that are classified 
in the form of “points”. Information on efficacy and safety 
can also be extracted from monographs and articles on plant 
species published in indexed journals (Brasil, 2010c).
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The selection of the books was made through as-
sessing techni cal-scientific references and those selected 
are divided into three groups (A, B and C), according 
to the theoretical reference and the monograph model 
for medicinal plants found in each book. Each reference 
must inform the herbal derivative used, the plant part this 
derivative is from, how it is extracted, its recommended 
posology and therapeutic indication in order to prove its 
safety and efficacy. 
The simplified registration species list, IN 05/08, 
comprises 36 plant species. Companies must follow all 
parameters that are specified in the list mentioned, which 
are: plant organ, chemical standard / marker, plant deri-
vative, therapeutic indications / actions, daily dose, route 
of administration and restrictions of use. This list was de-
veloped considering the various scien tific papers published 
on selected species for simplified registration. Thus, if the 
plant is present in this list, it is not necessary to submit any 
additional safety and efficacy data (Brasil, 2008b). 
The safety and efficacy data can also be confirmed 
through the observation of traditional use, ethnopharmaco-
logy or ethno-oriented studies and use, technical-scientific 
documentation, or other publications that show a period 
equal to 20 years or more of proven efficacy and safety of 
the product. The proposed period of use for the registered 
medicinal product, in this case, must be occasional or short 
(Brasil, 2010c). 
The use of medicinal plants, mostly in the form of 
infusions and decoctions, supports the ethnopharmacolo-
gical studies, and the companies, when filing for registra-
tion of their herbal products, should follow the traditional 
use patterns as closely as possible. Such caution is neces-
sary to ensure the similarity of the chemical profile of the 
re gistered medicinal product to its traditional use. 
Only when the product safety and efficacy cannot 
be accomplished by one of the three mentioned ways 
above are preclinical and clinical trials required for a 
specific product. For herbal medicine products, there is 
a guide to conducting preclinical toxicological trials (RE 
90/04) (Brasil, 2004b). This guide sets out the minimum 
acceptable criteria for conducting acute, sub-chronic and 
chronic toxicological studies. Additional reproductive 
toxicity tests and toxicology studies must be conducted for 
topical products (skin sensitivity; skin and eye irritability). 
The studies shall be conducted using standardized herbal 
medicines product samples or the herbal derivatives from 
which they are originated (Brasil, 2004b). 
Once preclinical tests are finalized, clinical studies 
are necessary to confirm the proposed actions and safety 
of the drug. In addition to these studies, it is also impor-
tant to ascertain pharmacokinetic and pharmacodynamic 
effects and occurrence of possible adverse events. There 
are Brazilian Health Council norms (CNS) for this purpo-
se: Resolution 196/96 (Brasil, 1996), which regulates any 
clinical studies conducted in the country, and Resolution 
251/97 (Brasil, 1997), specific for drugs and medicines. In 
order to complement the specific requirements for the re-
gistration of medicinal products, ANVISA also published 
RDC 39 in 2008 as a guide to the conduction of clinical 
trials (Brasil, 2008a). 
Good Clinical Practice guidelines shall be applied to 
all stages of clinical trials to ensure that the requirements 
of quality control and ethics are covered (WHO, 2008). 
ANVISA’s guide on Good Clinical Practice determines 
that, before undergoing any research, the study proposals 
must be approved by ANVISA then followed by a Special 
Announcement (CE) issuance (Brasil, 2008a). 
The World Health Organization (WHO) guide on 
clinical research states that the information on the plant 
species’ traditional usage that is going to be clinically tes-
ted should be taken into consideration, and, in this case, the 
chemical composition and form of manufacturing should 
be similar to the traditional wording used. The parameters 
related to the quality of the product to be tested must also 
be obser ved. In the case of herbal medicines, the guarantee 
of the identity of the plant species, its standardization and 
the presence of potential contaminants and adulterations 
must be observed (OMS, 2008). 
Registering medicinal products requires compa-
nies to prove, in addition to the safety and efficacy of 
the product, that they have a pharmacovigilance system 
that is able to detect adverse effects or harm caused by 
the use of their products. RDC 04/09 presents guidelines 
on pharmacovigilance to support the regulated sector 
(Brasil, 2009a). 
QUALITY CONTROL INFORMATION 
It is necessary to conduct various tests in order 
to de monstrate product’s quality. Such tests verify, for 
example, the identity of plant species and the absence or 
presence of contaminants within acceptable limits. Control 
is performed in all production stages: herbal drugs, herbal 
derivatives, and herbal medicines (Brasil, 2010b). 
Contamination of medicinal plants by fungi may 
give rise to mycotoxins, e.g. aflatoxins, which are car-
cinogenic (Bugno, 2006). Ways of avoiding this type of 
contamination include constant monitoring and evaluation 
of these substances in raw plant materials. There is no 
specific regulation for aflatoxin limits in herbal medicines 
in Brazil. The WHO has determined the analysis of afla-
toxin types B1, B2, G1, and G2. The presence of any of 
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these in raw medicinal plant material is regarded as highly 
dangerous (Bugno et al., 2006). 
Other contaminants that must be observed are: inor-
ganic waste material through ash tests; bacteria and fungi; 
other plant species, or even parts of the plant species other 
than the one indicated as a place of greater concentration 
of actives. The plant species gathering or cropping site 
and whether methods of eliminating contaminants were 
used must be informed followed by the search for possible 
residues. 
Identifying a plant species involves sensorial or or-
ganoleptic analysis, botanical identification (macroscopic 
and microscopic analysis), and phytochemical prospecting 
(Brasil, 2010b). 
For herbal derivatives, extraction methods and the 
detection of solvent residues should be reported. Physico-
chemical tests are requested including: organoleptic cha-
racterization, solid residues, pH, alcoholic content, density 
(for liquid extracts); moisture loss due to drying, apparent 
solubility and density (for dry extracts); refractive index, 
optical rotation (for essential oils); ester, iodine (for fixed 
oils) and acidity indexes (Brasil, 2010b). 
The qualitative and quantitative analysis of markers 
via chromatographic techniques and spectrometric must 
be presented. RDC 14/09 lays down specific requisites 
based on quality assurance, requiring reprodu cibility of 
herbal medicines. Marker quantitative control can be 
replaced by the therapeutic activity’s biological control 
(Brasil, 2010b). 
The company that applies for the herbal medicine 
regis tration should preferably use the methodologies des-
cribed in pharmacopeias recognized by ANVISA (RDC 
37/2009) for quality control of herbal materials, excipients 
and her bal medicine (Brasil, 2009d). Otherwise it is ne-
cessary to validate the methodologies used. To do so, the 
method must present the parameters stated by RE 899/03 
(Brasil, 2003a); despite having been developed for syn-
thetic drugs, they are also applicable to herbal medicines. 
Bioa nalytical method parameters must be used. 
Once the herbal medicine registration is granted, any 
changes made to the product should be communicated to 
ANVISA, accompanied by proof of the product’s conti-
nued quality, safety and efficacy. Companies must follow 
the procedures specified in the “Guide to making changes 
and additions to post-registered herbal medicines”, RE 
91/04 (Brasil, 2004c). 
OTHER APPLICABLE REGULATIONS
Other regulations can be applied to herbal medici-
nes, including: restriction of sale criteria, i.e. whether or 
not the medicinal product will be sold as a prescription 
medicine (Brasil, 2003b); a stability study guide (Brasil, 
2005a), good manufacturing practices, quality control and 
storage outsourcing (Brasil, 2007), medicinal products 
advertising norms (BRASIL, 2008c), standardization of 
package leaflet (Brasil, 2009b), packaging models and 
wordings (Brasil, 2009c), and good manufacturing prac-
tices for raw material (Brasil, 2005b). 
RDC 138/03 sets down the medicinal products that 
do not require prescription prior to sale, except for paren-
terally administered products. All therapeutic indications 
that are not described in this list are sold under prescription 
(Brasil, 2003b). 
RE 01/05 provides for the information that must be 
present in all stability study reports for each pharmaceu-
tical form, and also covers stability study monitoring and 
photostability. The stability study of medicines should be 
carried out in both accelerated mode as well as long las-
ting mode. The accelerated study is designed to accelerate 
the chemical degradation and / or physical changes of a 
pharmaceutical product in forced storage conditions. The 
long-term study is designed for the verification of physical, 
chemical, biological, and microbiological characteristics 
of a pharmaceutical product during (and optionally after) 
the expected expiry date. The results are used for the esta-
blishment or confirmation of the product’s expiry date and 
recommendations for the appropriate storage conditions 
for the product at the marketing point and by the user 
(Brasil, 2005b). 
RDC 47/09 lays down rules for patients and health 
professionals concerning leaflets. In parallel, package le-
aflets for herbal medicines have been standardized. There 
are leaflets standardized for 18 plant species in order to 
ensure that standardized product information is available 
to the population (Brasil, 2009c). 
RDC 71/09 states medicine labeling parameters. It 
was published in order to improve the form and content of 
the labels of all registered medicinal products marketed in 
Brazil. It also introduced the obligation of manufacturing 
labels to appear in Braille (Brasil, 2009b). 
Labels must contain alerts on after-preparation 
conservation of the medicinal products and inform that its 
expiry date is reduced once the package is open. The inclu-
sion of identification and security mechanisms to enable 
tracking of the product from manufacturing to dispensing 
are also included in the labels (Brasil, 2009d).
CONCLUSION
Adjustments to the entire production chain of herbal 
medicines offer safe, efficacious quality products to the 
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population, avoiding health problems, such as poisoning, 
aggravation of diseases, and therapeutic failures. 
This updating of the standard herbal medicine 
registration caters to the needs of PNPMF, PNPIC, and 
introduces alternatives for herbal medicine quality control. 
Despite boasting one of the world’s greatest biodiversity 
and being one of the countries that publishes the largest 
number of scientific articles on medicinal plants and her-
bal medicines, Brazil still has an unimpressive number 
of herbal medicines registered containing Brazilian plant 
species. Thus, knowledge of the regulatory surveillance 
health system, participation in the establishment of regula-
tion standards, whether through direct action of ANVISA 
or through contributions from public consultations, and 
performance of tests in accordance to the prevailing norms 
are essential for the positive development of the sector’s 
regulation system, providing a scientific character to the 
legislation. Studies concerning regulatory requirements, so 
that they can be leveraged in the registration of medicines 
and in improving herbal medicines registration process, 
can contribute to the introduction of safe, efficacious, and 
good quality products in the market.
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